Glenmark Pharma is first to launch in India, a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin for Type 2 Diabetes in Adults with Co-morbidities

October 18, 2023

- Zita® DM is the brand name for the first triple-drug FDC of Teneligliptin, Dapagliflozin, and Metformin in India.

- Zita® DM helps improve glycemic control in adult patients with high HbA1c and/or other co-morbidities, those  patients whose diabetes is uncontrolled by metformin;

and also those who require the addition of Teneligliptin and Dapagliflozin as separate drugs, thereby improving adherence with a single-dose pill.
 
- Priced at INR 14 per tablet (per day), it will lower the daily cost of therapy by 30%; making it affordable. 


  Mumbai, India, October 18, 2023: Glenmark Pharmaceuticals Limited (Glenmark Pharma), a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widely used Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita®  DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and  Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.  

On the occasion of the launch, Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated, “India has the second‐largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion,  along with other co‐morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers. Being a leader in treating diabetes, we are proud to introduce  Zita® DM, a novel and affordable anti‐diabetic drug, which helps improve glycemic control among adult patients with high HbA1c and other co‐morbidities; while also reducing major renal and cardiac adverse events.  With this robust profile, we are positive Zita® DM will facilitate patient adherence to chronic diabetes  treatments.” 

Glenmark’s Zita® portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita® DM, Zita® the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.  

According to IQVIA™ sales data for the 12-month period ending August 2023 (MAT August 2023), the market for oral anti-diabetic drugs in India is estimated to be INR 12,522 crores, with an annual growth of 6.5% against the corresponding period last year (MAT August 2022). As per the ICMR-INDIAB study conducted between 17th October 2008 and 17 December 2020, the overall weighted prevalence of diabetes was 11.4%
  

Glenmark’s Leadership in the Diabetes Segment 

Glenmark has a strong legacy of bringing in new, effective, and affordable treatment options for diabetic patients,  especially those with uncontrolled Type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor,  Teneligliptin (Zita Plus® and Ziten®), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus® and Ziten M®). Glenmark later introduced Remogliflozin (Remo® and Remozen™), a novel SGLT-2 inhibitor in 2019; and  subsequently, its combinations (Remo-V®, Remozen™-V, Remo MV®, and Remozen™ MV). Glenmark followed that up with the launch of Sitagliptin (Sitazit®) and its FDCs in 2022. Then came Lobeglitazone (LOBG®) and additional FDCs of Teneligliptin, including its combinations with Pioglitazone (Zita Pio™), Pioglitazone + Metformin  (Zita®-PioMet), and Dapagliflozin (Zita-D™). 


 

About Glenmark Pharmaceuticals Ltd  

Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company,  with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory,  dermatology, and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and  Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies  Ranked by Sales, 2021. The company has also been Great Place To Work® Certified™ in India for FY 2023. Glenmark’s Green  House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target Initiative (SBTi),  making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions.

> <
  • GlenmarkGlenmark Pharmaceuticals
 
download

Glenmark Pharmaceuticals 

India

“India has the second-largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion, along with other co-morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers. Being a leader in treating diabetes, we are proud to introduce Zita® DM, a novel and affordable anti-diabetic drug, which helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events. With this robust profile, we are positive Zita® DM will facilitate patient adherence to chronic diabetes treatments.”

Author,
Alok Malik, President & Business Head - India Formulations, Glenmark Pharma

Need good help?

Check out our Services

Press Release Distribution & Writing Services

Submit Your Brand Story

More News From Glenmark Pharmaceuticals

Image
Nov 14, 2023

Highlights for Q2 FY 2023‐24    ∙ Europe Business grew by 58.4% to Rs. 5,997 Mn.  ∙ RoW Business grew by 19% to Rs. 7,324 Mn.  ∙ India Business grew by 2.8% to Rs. 11,217 Mn.  ∙ ...

Image
Nov 07, 2023

Mahwah, New Jersey, USA and Mumbai, India, November 7, 2023: Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluphenazine ...

Image
Oct 17, 2023

Mahwah, New Jersey, USA and Mumbai, India, October 17, 2023: Glenmark Pharmaceuticals Ltd.   (Glenmark) has received final approval from the United States Food & Drug Administration (U.S. ...

Similar News

Image
Nov 20, 2023

Mumbai, November 20, 2023: The Banking and Financial Services sector has been a structural growth story in India, which is evident in its outperformance over the broader Nifty 50 Index on all 10-year periods. The ...

Image
Nov 20, 2023

Chennai, November 2023: Indian Renewable Energy Development Agency Limited, a Government of India (“GoI”) enterprise notified as a “Public Financial Institution” (“PFI”) registered as ...